Table 1. Anti-CD38 monoclonal antibody outcome in multiple myeloma: upfront and relapsed indications.
| ALCYONE (dara-VMP) |
MALA (dara-Rd) |
CASSIOPEIA (dara-VTd) |
POLLUX (dara-Rd) |
APOLLO (dara-Pd) |
CANDOR (dara-Kd) |
ICARIA (isa-Pd) |
IKEMA (isa-Kd) |
|
|---|---|---|---|---|---|---|---|---|
| Number of patients |
350 | 368 | 543 | 283 | 151 | 312 | 154 | 179 |
| Median number of prior lines |
NA | NA | NA | NA | 2 | 2 | 3 | 2 |
| ORR/≥CR, % | 90.9/46 | 92.9/50 | /26 | 92.9/56.6 | 69/25 | 84/29 | 63/5 | 87 |
| MRD 10−5 negativity |
28 | 28.8 | 64 | 30.4 | 9 | 14 | - | 30 |
| PFS, months | Median: 36.4 | 48-month PFS ≈ 60% |
48-month PFS ≈ 70% |
Median: 44.5 | Median: 12.4 | 18-month PFS ≈ 62% |
Median: 11.5 | Median: 35.7 |
| OS, months | 36-month OS: 78% |
- | - | - | - | - | Median: 24.6 | - |
CR, complete response; MRD, minimal residual disease; NA, not available; ORR, overall response rate; OS, overall survival; PFS, progression-free survival